BMS Expands Immuno-Oncology Pipeline with Five Prime Partnership
By Heather Cartwright
Pharma Deals Review: Vol 2014 Issue 4 (Table of Contents)
Published: 12 Apr-2014
DOI: 10.3833/pdr.v2014.i4.2018 ISSN: 1756-7874
Section: Research & Development
Fulltext:
Abstract
In order to add next-generation therapeutics to its already broad immuno-oncology pipeline, Bristol-Myers Squibb has partnered with Five Prime Therapeutics to discover novel interacting proteins in two undisclosed immune checkpoint pathways using Five Prime’s target discovery platform and to discover and preclinically develop immunotherapeutics against these targets...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS